Lab Work for Cardiac/Circ Problem: 15.8% of denials overturned
In 101 California IMR decisions from 2007 to 2025, reviewers overturned 16 (15.8%). In the last five years: 22.2% of 18. 6 were medical-necessity disputes, 95 experimental/investigational.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2021 | 4 | 0.0% |
| 2022 | 4 | 0.0% |
| 2023 | 6 | 50.0% |
| 2024 | 3 | 33.3% |
| 2025 | 1 | 0.0% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Guidelines or criteria citedThe findings cite guidelines, criteria or a standard of care. | 57 | 3.5% | 15.8% |
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 17 | 29.4% | 15.8% |
| Records did not supportThe findings say the documentation did not show what was needed (usually an upheld denial). | 7 | 14.3% | 15.8% |
| Experimental or investigationalThe findings discuss whether the treatment is experimental. | 3 | 0.0% | 15.8% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for a blood test (advanced lipoprotein testing). Professional society guidelines do not advocate routine advanced lipoprotein testing given the predominance of risk assessment and management based on traditional lipid levels. However, advanced lipoprotein testing may be utilized in patients deemed to be at borderline 10-year risk of arteriosclerotic cardiovascular disease …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for a blood test (advanced lipoprotein testing). This patient has a history of hyperlipidemia and silent stroke. Despite the proven clinical utility of standard lipid testing for risk management, there remains a significant burden of atherosclerotic cardiovascular disease (ASCVD) events that remain unaddressed. …”
“Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for AlloMap molecular expression testing. Findings: The physician reviewer found that this patient underwent Allomap testing status post heart transplantation so that the provider could assess the risk for organ rejection. AlloMap is a blood test used to identify heart transplant recipients who might be at risk for organ rejection. …”
And one the reviewer upheld
“The physician reviewer found that Nature of Statutory Criteria/Case Summary:A patient has requested reimbursement for advanced lipoprotein testing, including lipoprotein (a). Advanced lipoprotein testing may provide additional risk stratification for atherosclerotic cardiovascular disease; however, current clinical guidelines do not recommend routine use in low risk individuals or in patients without established indications. Management decisions in most patients remain based on …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Lab Work denials for Cardiac/Circ Problem overturned?
In 101 California IMR decisions from 2007 to 2025, reviewers overturned 16 (15.8%). In the last five years: 22.2% of 18. 6 were medical-necessity disputes, 95 experimental/investigational.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.